Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients

Renée L. Mulder; Marios Paulides; Thorsten Langer; Leontien C.M. Kremer; Elvira C. van Dalen

doi:10.1002/14651858.CD006300.pub4

Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients

Renée L. Mulder^*, Marios Paulides, Thorsten Langer, Leontien C.M. Kremer, Elvira C. van Dalen

^*Corresponding author for this work

Clinic of Pediatric and Adolescent Medicine

Emma Kinderziekenhuis

9 Citations (Scopus)

Abstract

Background: Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the state of evidence on the effectiveness of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with sarcoma. Objectives: The primary obective was to compare the effectiveness, that is response rate, event-free survival and overall survival, of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma. Secondary objectives were to determine effects of these agents on toxicities (including late effects) and quality of life. Search methods: We searched CENTRAL (The Cochrane Library 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015) with prespecified terms. In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (www.controlled-trials.com; searched June 2015). Selection criteria: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis). Chemotherapy other than either cyclophosphamide or ifosfamide should have been the same in both treatment groups. Data collection and analysis: Two authors independently performed the study selection. Main results: No studies meeting the inclusion criteria of the review were identified. Authors' conclusions: No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified. Therefore no definitive conclusions can be made about the effects of cyclophosphamide and ifosfamide in these patients. Based on the currently available evidence, we are not able to give recommendations for clinical practice. More high-quality research is needed.

Original language	English
Article number	CD006300
Journal	Cochrane Database of Systematic Reviews
Volume	2015
Issue number	9
ISSN	1469-493X
DOIs	https://doi.org/10.1002/14651858.CD006300.pub4
Publication status	Published - 30.09.2015

Funding

Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are co-authors of this review and therefore they could not act as the Co-ordinating Editors for this review. Wim J Tissing (Department of Pediatric Oncology/Hematology, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands) was willing to take on this task, for which we thank him. Also, we thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, and Wolfgang Stöhr for his help in preparing the protocol for this review. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Access to Document

10.1002/14651858.CD006300.pub4

Cite this

@article{0f3cac93d76944b492091369223101e7,

title = "Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients",

abstract = "Background: Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the state of evidence on the effectiveness of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with sarcoma. Objectives: The primary obective was to compare the effectiveness, that is response rate, event-free survival and overall survival, of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma. Secondary objectives were to determine effects of these agents on toxicities (including late effects) and quality of life. Search methods: We searched CENTRAL (The Cochrane Library 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015) with prespecified terms. In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (www.controlled-trials.com; searched June 2015). Selection criteria: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis). Chemotherapy other than either cyclophosphamide or ifosfamide should have been the same in both treatment groups. Data collection and analysis: Two authors independently performed the study selection. Main results: No studies meeting the inclusion criteria of the review were identified. Authors' conclusions: No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified. Therefore no definitive conclusions can be made about the effects of cyclophosphamide and ifosfamide in these patients. Based on the currently available evidence, we are not able to give recommendations for clinical practice. More high-quality research is needed.",

author = "Mulder, \{Ren{\'e}e L.\} and Marios Paulides and Thorsten Langer and Kremer, \{Leontien C.M.\} and \{van Dalen\}, \{Elvira C.\}",

note = "Funding Information: Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are co-authors of this review and therefore they could not act as the Co-ordinating Editors for this review. Wim J Tissing (Department of Pediatric Oncology/Hematology, Beatrix Children{\textquoteright}s Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands) was willing to take on this task, for which we thank him. Also, we thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, and Wolfgang St{\"o}hr for his help in preparing the protocol for this review. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA). Publisher Copyright: {\textcopyright} 2015 The Cochrane Collaboration. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2015",

month = sep,

day = "30",

doi = "10.1002/14651858.CD006300.pub4",

language = "English",

volume = "2015",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

number = "9",

}

TY - JOUR

T1 - Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients

AU - Mulder, Renée L.

AU - Paulides, Marios

AU - Langer, Thorsten

AU - Kremer, Leontien C.M.

AU - van Dalen, Elvira C.

N1 - Funding Information: Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are co-authors of this review and therefore they could not act as the Co-ordinating Editors for this review. Wim J Tissing (Department of Pediatric Oncology/Hematology, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands) was willing to take on this task, for which we thank him. Also, we thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, and Wolfgang Stöhr for his help in preparing the protocol for this review. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA). Publisher Copyright: © 2015 The Cochrane Collaboration. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2015/9/30

Y1 - 2015/9/30

N2 - Background: Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the state of evidence on the effectiveness of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with sarcoma. Objectives: The primary obective was to compare the effectiveness, that is response rate, event-free survival and overall survival, of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma. Secondary objectives were to determine effects of these agents on toxicities (including late effects) and quality of life. Search methods: We searched CENTRAL (The Cochrane Library 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015) with prespecified terms. In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (www.controlled-trials.com; searched June 2015). Selection criteria: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis). Chemotherapy other than either cyclophosphamide or ifosfamide should have been the same in both treatment groups. Data collection and analysis: Two authors independently performed the study selection. Main results: No studies meeting the inclusion criteria of the review were identified. Authors' conclusions: No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified. Therefore no definitive conclusions can be made about the effects of cyclophosphamide and ifosfamide in these patients. Based on the currently available evidence, we are not able to give recommendations for clinical practice. More high-quality research is needed.

AB - Background: Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the state of evidence on the effectiveness of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with sarcoma. Objectives: The primary obective was to compare the effectiveness, that is response rate, event-free survival and overall survival, of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma. Secondary objectives were to determine effects of these agents on toxicities (including late effects) and quality of life. Search methods: We searched CENTRAL (The Cochrane Library 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015) with prespecified terms. In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (www.controlled-trials.com; searched June 2015). Selection criteria: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis). Chemotherapy other than either cyclophosphamide or ifosfamide should have been the same in both treatment groups. Data collection and analysis: Two authors independently performed the study selection. Main results: No studies meeting the inclusion criteria of the review were identified. Authors' conclusions: No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified. Therefore no definitive conclusions can be made about the effects of cyclophosphamide and ifosfamide in these patients. Based on the currently available evidence, we are not able to give recommendations for clinical practice. More high-quality research is needed.

UR - https://www.scopus.com/pages/publications/84964694435

U2 - 10.1002/14651858.CD006300.pub4

DO - 10.1002/14651858.CD006300.pub4

M3 - Scientific review articles

C2 - 26421585

AN - SCOPUS:84964694435

SN - 1469-493X

VL - 2015

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 9

M1 - CD006300

ER -

Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this